Immunovant, Inc.
IMVT
$31.43
-$0.18-0.57%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -505.61M | -464.20M | -464.69M | -447.30M | -413.84M |
| Total Depreciation and Amortization | 409.00K | 422.00K | 420.00K | 404.00K | 377.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 55.82M | 56.37M | 55.30M | 54.63M | 49.62M |
| Change in Net Operating Assets | 42.06M | -15.48M | -21.99M | -24.82M | -12.03M |
| Cash from Operations | -407.31M | -422.89M | -430.95M | -417.09M | -375.87M |
| Capital Expenditure | -8.00K | -201.00K | -381.00K | -577.00K | -759.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -8.00K | -201.00K | -381.00K | -577.00K | -759.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 596.26M | 1.04B | 480.91M | 457.04M | 454.81M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -504.00K | -905.00K | -319.00K | -319.00K | -319.00K |
| Cash from Financing | 595.76M | 1.04B | 480.59M | 456.72M | 454.49M |
| Foreign Exchange rate Adjustments | -299.00K | 201.00K | -325.00K | -154.00K | 747.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 188.14M | 619.84M | 48.93M | 38.91M | 78.61M |